Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Payables (2016 - 2025)

Historic Payables for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $556000.0.

  • Gyre Therapeutics' Payables rose 8349.83% to $556000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $556000.0, marking a year-over-year increase of 8349.83%. This contributed to the annual value of $108000.0 for FY2024, which is 6957.75% down from last year.
  • Gyre Therapeutics' Payables amounted to $556000.0 in Q3 2025, which was up 8349.83% from $71000.0 recorded in Q2 2025.
  • Gyre Therapeutics' Payables' 5-year high stood at $7.7 million during Q4 2022, with a 5-year trough of $5000.0 in Q2 2023.
  • Moreover, its 5-year median value for Payables was $330000.0 (2024), whereas its average is $1.6 million.
  • In the last 5 years, Gyre Therapeutics' Payables plummeted by 9966.0% in 2023 and then soared by 532000.0% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Payables (Quarter) stood at $6.4 million in 2021, then increased by 19.64% to $7.7 million in 2022, then plummeted by 95.38% to $355000.0 in 2023, then tumbled by 69.58% to $108000.0 in 2024, then surged by 414.81% to $556000.0 in 2025.
  • Its Payables stands at $556000.0 for Q3 2025, versus $71000.0 for Q2 2025 and $122000.0 for Q1 2025.